News | February 24, 2021
Aurobindo Pharma to acquire 26% ownerships solar power companies
The company will be holding 26% of the share capital in each of the solar power generating companies.
The company will be holding 26% of the share capital in each of the solar power generating companies.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The product will be launched in Q1FY26
The company does not expect this development to have any material impact on the current business operations
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Subscribe To Our Newsletter & Stay Updated
